Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on October 16, 2007. The report addresses a change in accounting classification regarding the PharMerica Segment following the July 31, 2007, spin-off of its institutional pharmacy business, PharMerica Long-Term Care, which merged with Kindred Pharmacy Services to form PharMerica Corporation (PMC).
Key Financial Metrics
- Diluted EPS (Continuing Operations) - First 9 Months FY2007: $1.99
- Revised FY2007 Diluted EPS (Continuing Operations) Guidance: $2.58 to $2.66
- Q3 FY2007 Diluted EPS (Continuing Operations) Implied Range: $0.59 to $0.67
- PharMerica Long-Term Care Contribution to FY2007 EPS: $0.08 (through spin-off date)
- PharMerica Long-Term Care Contribution to Q3 FY2007 EPS: $0.01
The filing does not provide specific values for total revenue, net profit, cash flow, margins, debt, or liquidity for the period.
Material Changes Versus Prior Period
The primary material change is the decision not to reclassify the PharMerica Long-Term Care business as a discontinued operation, contrary to a previous disclosure in the June 30, 2007, Quarterly Report. This decision was made because the company entered into a pharmaceutical distribution agreement with PMC, resulting in significant continuing gross cash flows from the disposed business. Consequently, historical results for PharMerica Long-Term Care will remain in continuing operations. The company will rename the previously reported PharMerica segment to "Other" in future filings.
Guidance, Outlook, and Risks
Guidance Update: Management clarified its estimate for fiscal year 2007 diluted earnings per share from continuing operations to a range of $2.58 to $2.66. This update incorporates the $0.08 contribution from PharMerica Long-Term Care prior to the spin-off.
Outlook: The company remains optimistic about fiscal year 2008 and expects performance to align with its long-term financial goals.
Unusual Items: The filing references EITF Issue No. 03-13 regarding the determination of discontinued operations, which drove the accounting change.
Investor Verification Checklist
- Verify the unaudited financial information for PharMerica Long-Term Care and PMSI provided in Exhibit 99.2.
- Confirm the terms of the pharmaceutical distribution agreement with PharMerica Corporation (PMC) to understand the source of continuing cash flows.
- Review the news release (Exhibit 99.1) for detailed quarterly breakdowns of the PharMerica Segment.
- Monitor future filings to ensure the PharMerica segment is correctly reclassified as "Other."